Ultragenyx Pharmaceutical Inc. (RARE) Guidance & Earnings Results
On 2026-08-04 Ultragenyx Pharmaceutical Inc. reaffirmed guidance: "Full year 2026 revenue guidance…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RAREUltragenyx Pharmaceutical Inc.Follow RARE — free
—
Price chart with a free account
- Market cap
- 1.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 4 Aug 26 | Reaffirmed | Full year 2026 revenue guidance $730-760M · full year |
| 5 May 26 | Reaffirmed | FY2026 total revenue $730-760M; Crysvita $500-520M; Dojolvi $100-110M; combined R&D and SG&A flat to slightly down vs 2025; 2027 combined R&D and SG&A decrease at least 15% · full year |
| 12 Feb 26 | Reaffirmed | 2026 total revenue from current products expected to be between $730 million to $760 million · full year |
| 12 Jan 26 | Raised | Total revenue $672-674M vs prior guidance top end · full year |
| 4 Nov 25 | Reaffirmed | Total revenue $640M-$670M, Crysvita $460M-$480M, Dojolvi $90M-$100M · full year |
| 5 Aug 25 | Reaffirmed | FY2025 total revenue $640-670M; Crysvita $460-480M; Dojolvi $90-100M; net cash used in operations expected to modestly increase vs 2024; path to GAAP profitability in 2027 · full year |
Ultragenyx Pharmaceutical Inc. — questions
- What guidance did Ultragenyx Pharmaceutical Inc. give?
- On 2026-08-04: "Full year 2026 revenue guidance $730-760M"
- When does Ultragenyx Pharmaceutical Inc. report earnings?
- Ultragenyx Pharmaceutical Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from Ultragenyx Pharmaceutical Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.